CALGB C80702: A Phase III Trial of 6 versus 12 Treatments of Adjuvant FOLFOX plus Celecoxib or Placebo for Patients with Resected Stage III Colon Cancer

Print this page

CALGB C80702: A Phase III Trial of 6 versus 12 Treatments of Adjuvant FOLFOX plus Celecoxib or Placebo for Patients with Resected Stage III Colon Cancer

To compare disease-free survival of patients with stage III colon cancer randomized to standard chemotherapy (FOLFOX) or standard chemotherapy with 3 years of celecoxib 400 mg daily.

Protocol Number071008
Principal InvestigatorRebecca Moss
PhasePhase III
ScopeNational
Applicable Disease SitesColon
Therapies InvolvedChemotherapy multiple agents systemic
Drugs InvolvedFOLFOX
CELECOXIB/PLACEBO
Participating InstitutionsRobert Wood Johnson University Hospital at Hamilton
Rutgers Cancer Institute of New Jersey

For further information on this clinical trial, please contact us at 732-235-8675 or cinjclinicaltrials@umdnj.edu.